| 1 |
Bray F， Laversanne M， Sung H， et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin， 2024， 74（3）: 229-263.
|
| 2 |
Biganzoli L， Battisti NML， Wildiers H， et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists （EUSOMA） and the International Society of Geriatric Oncology （SIOG） ［J］. Lancet Oncol， 2021， 22（7）: e327-e340.
|
| 3 |
Carleton N， Nasrazadani A， Gade K， et al. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women ［J］. Lancet Healthy Longev， 2022， 3（1）: e54-e66.
|
| 4 |
Lei S， Zheng R， Zhang S， et al. Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030 ［J］.Cancer Biol Med， 2021， 18（3）: 900-909.
|
| 5 |
Shi Z， Lin J， Wu Y， et al. Burden of cancer and changing cancer spectrum among older adults in China: Trends and projections to 2030［J］. Cancer Epidemiol， 2022， 76: 102068.
|
| 6 |
Allison KH， Hammond MEH， Dowsett M， et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update［J］. Arch Pathol Lab Med， 2020， 144（5）: 545-563.
|
| 7 |
Wolff AC， Hammond MEH， Allison KH， et al. Human epidermal growth factor receptor 2 testing in beast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update ［J］. J Clin Oncol， 2018， 36（20）: 2105-2122.
|
| 8 |
Bukholm IR， Bukholm G， Holm R， et al. Association between histology grade， expression of HsMCM2， and cyclin A in human invasive breast carcinomas ［J］. J Clin Pathol， 2003， 56（5）: 368-373.
|
| 9 |
Goldhirsch A， Winer EP， Coates AS， et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 ［J］. Ann Oncol， 2013， 24（9）: 2206-2223.
|
| 10 |
梅放， 柳剑英， 薛卫成. 浸润性乳腺癌的组织学分级: Nottingham组织学分级系统 ［J］. 中华病理学杂志， 2019， 48（8）: 659-664.
|
| 11 |
Cortazar P， Zhang L， Untch M， et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis ［J］. Lancet， 2014， 384（9938）: 164-172.
|
| 12 |
Dotan E， Walter LC， Browner IS， et al. NCCN Guidelines® Insights:Older Adult Oncology， Version 1.2021 ［J］. J Natl Compr Canc Netw，2021， 19（9）: 1006-1019.
|
| 13 |
Bagegni NA， Peterson LL. Age-related disparities in older women with breast cancer ［J］. Adv Cancer Res， 2020， 146: 23-56.
|
| 14 |
Williams AD， Dang CT， Sevilimedu V， et al. Neoadjuvant chemotherapy for breast cancer in the elderly: Are we accomplishing our treatment goals? ［J］. Ann Surg Oncol， 2022， 29（13）: 8002-8011.
|
| 15 |
云涌洋， 张晓丹， 程元甲. HER2 阳性乳腺癌TCHP 方案新辅助治疗的不良反应分析 ［J/OL］. 中华临床医师杂志（电子版）， 2022，16（11）: 1075-1080.
|
| 16 |
Spring L， Greenup R， Niemierko A， et al. Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer ［J］. J Natl Compr Canc Netw，2017， 15（10）: 1216-1223.
|
| 17 |
Bear H D， Anderson S， Brown A， et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27 ［J］. J Clin Oncol，2003， 21（22）: 4165-4174.
|
| 18 |
Guarneri V， Broglio K， Kau SW， et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors ［J］. J Clin Oncol， 2006， 24（7）:1037-1044.
|
| 19 |
林燕， 孙强， 宋雨， 等. 中国老年乳腺癌诊疗专家共识（2023 版） ［J］.中国研究型医院， 2023， 10（5）: 1-8.
|
| 20 |
Spring LM， Gupta A， Reynolds KL， et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: A systematic review and meta-analysis ［J］. JAMA Oncol， 2016， 2（11）: 1477.
|
| 21 |
崔军威， 刘荫华， 刘晓岭. 双靶联合化疗药物在HER2 阳性乳腺癌新辅助治疗中的疗效及其影响因素 ［J/OL］. 中华临床医师杂志（电子版）， 2022， 16（11）: 1062-1067.
|
| 22 |
Brain E， Caillet P， De Glas N， et al. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology ［J］. J Geriatr Oncol， 2019，10（6）: 1003-1013.
|
| 23 |
Shuai Y， Ma L. Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy ［J］. Pathol Res Pract， 2019， 215（1）: 29-33.
|
| 24 |
Krystel-Whittemore M， Xu J， Brogi E， et al. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy ［J］. Breast Cancer Res Treat， 2019， 177（1）: 61-66.
|
| 25 |
Buzdar AU， Ibrahim NK， Francis D， et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab， paclitaxel， and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer ［J］. J Clin Oncol， 2005， 23（16）: 3676-3685.
|
| 26 |
Gianni L， Pienkowski T， Im YH， et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced， inflammatory， or early HER2-positive breast cancer（NeoSphere）: a randomised multicentre， open-label， phase 2 trial ［J］.Lancet Oncol， 2012， 13（1）: 25-32.
|
| 27 |
岳瑞雪， 孔令欣， 郝鑫. 乳腺癌HER2 蛋白表达水平预测新辅助治疗疗效的真实世界研究［J/OL］. 中华临床医师杂志（电子版），2023， 17（7）: 765-770.
|
| 28 |
Houssami N， Macaskill P， Von Minckwitz G， et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy ［J］. Eur J Cancer， 2012， 48（18）:3342-3354.
|
| 29 |
von Waldenfels G， Loibl S， Furlanetto J， et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials ［J］. Oncotarget， 2018， 9（20）: 15168-15179.
|